Subscribe to RSS
DOI: 10.1055/s-0029-1217361
Unexpected Formation of Fluorine-Containing Multiply Substituted Dispirocyclohexanes from the Reaction of Ethyl-4,4,4-trifluoro-1,3-dioxobutanoate and 2-Arylideneindane-1,3-diones
Publication History
Publication Date:
12 June 2009 (online)
Abstract
In the presence of a catalytic amount of piperidine (10 mol%), reaction of ethyl 4,4,4-trifluoro-3-oxobutanoate 3 and 2-arylidene-indane-1,3-diones 4 gave the unexpected fluorine-containing multiply substituted dispirocyclohexanes 5 in good yields. The structures of compounds 5 were fully confirmed by spectroscopic methods and elemental analysis. A representative compound 5a was further confirmed by XRD analysis. A plausible reaction mechanism for the formation of compounds 5 was presented.
Key words
fluorine-containing - spiro compound - polysubstitution - 2-arylidene-indan-1,3-dione - ethyl 4,4,4-trifluoro-3-oxobutanoate
- Supporting Information for this article is available online:
- Supporting Information
-
1a
Gross U.Rüdiger S. Organo-Fluorine Compounds, In Methods of Organic Chemistry (Houben-Weyl) Vol. E10a:Baasner B.Hagemann H.Tatlow JC. Thieme; Stuttgart: 1999. p.18-26 -
1b
Smart BE. J. Fluorine Chem. 2001, 109: 3 -
2a
Banks RE.Smart BE.Tatlow JC. Organofluorine Chemistry: Principles and Commercial Applications Plenum Press; New York: 1994. -
2b
Hiyama T. Organofluorine Compounds: Chemistry and Properties Springer; Berlin: 2000. - 3
Burger’s
Medicinal Chemistry and Drug Discovery
Vol. 1:
Abraham DJ. John Wiley and Sons; New York: 2003. -
4a
Ismail FMD. J. Fluorine Chem. 2002, 118: 27 -
4b
Organofluorine
Compounds in Medicinal Chemistry and Biomedical Applications
Filler R.Kobayashi Y.Yagulpolskii LM. Elsevier; Amsterdam: 1993. -
4c
Welch JT.Ewarakrishnan SE. Fluorine in Bioorganic Chemistry John Wiley; New York: 1991. -
4d
Becker A. Inventory of Industrial Fluoro-Biochemicals Eyrolles; Paris: 1996. -
5a
Kozikowski AP. Acc. Chem. Res. 1984, 17: 410 -
5b
Howe RK.Shelton BR. J. Org. Chem. 1990, 55: 4603 -
5c
De Amici M.De Michelli C.Sani VM. Tetrahedron 1990, 46: 1975 -
5d
Caroll WA.Grieco PA. J. Am. Chem. Soc. 1993, 115: 1164 -
5e
Early WG.Oh T.Overman LE. Tetrahedron Lett. 1988, 29: 3785 -
5f
Ban Y.Taga N.Oishi T. Chem. Pharm. Bull. 1976, 24: 736 -
5g
Ban Y.Seto M.Oishi T. Chem. Pharm. Bull. 1975, 23: 2605 -
5h
Ban Y.Taga N.Oishi T. Tetrahedron Lett. 1974, 15: 187 -
5i
Van Tamelen EE.Yardley JP.Miyano M.Hinshaw WB. J. Am. Chem. Soc. 1969, 91: 7333 -
5j
Kobayashi J.Tsuda M.Ageme K.Shigemori H.Ishibashi M.Sasaki T.Mikami Y. Tetrahedron 1991, 47: 6617 -
5k
James DM.Kunze HB.Faulkner JD.
J. Nat. Prod. 1991, 54: 1137 -
5l
Sinclair A.Stockman RA. Nat. Prod. Rep. 2007, 24: 298 -
5m
Xu S.Arimoto H.Uemura D. Angew. Chem. Int. Ed. 2007, 46: 5746 -
5n
Clive DLJ.Yu M.Wang J.Yeh VSC.Kang S. Chem. Rev. 2005, 105: 4483 -
5o
Yashin NV.Averina EB.Grishin YK.Kuznetsova TS.Zefirov NS. Synthesis 2006, 279 -
5p
Bernard AM.Frongia A.Guillot R.Piras PP.Secci F.Spiga M. Org. Lett. 2007, 9: 541 -
5q
Salim H.Piva O. Tetrahedron Lett. 2008, 49: 2994 -
6a
Berger STA.Lemek T.Mayr H. ARKIVOC 2008, (x): 37 -
6b
Mosher WA.Brenne JL. J. Org. Chem. 1971, 36: 3383 -
6c
Zalukaevs LP.Anokhina I. J. Gen. Chem. USSR. 1964, 34: 834 ; Zh. Obshch. Khim. 1964, 34, 840 -
6d
Soliman FM.Said MM.Maigali SS. Heteroat. Chem. 1997, 8: 157 -
7a
Babu ARS.Raghunathan R. J. Heterocycl. Chem. 2006, 43: 1357 -
7b
Babu ARS.Raghunathan R.Gayatri G.Sastry GN. J. Heterocycl. Chem. 2006, 43: 1367 -
7c
Babu ARS.Raghunathan R. Synth. Commun. 2007, 37: 451 -
7d
Babu ARS.Raghunathan R. Tetrahedron Lett. 2006, 47: 9221 -
7e
Babu ARS.Raghunathan R. Tetrahedron 2007, 63: 8010 -
8a
Ramachary DB.Anebouselvy K.Chowdari NS.Barbas CF. J. Org. Chem. 2004, 69: 5838 -
8b
Ramachary DB.Chowdari NS.Barbas CF. Synlett 2003, 1910 - 9
Dhawan SN.Sharma M.Bajaj S.Sharma K.Sharma S. Heterocycles 2007, 71: 1509 - 10
Harig M.Kuck D. Eur. J. Org. Chem. 2006, 1647 -
11a
Zalukaevs LP.Anokhina I. J. Gen. Chem. USSR. 1964, 34: 834 ; Zh. Obshch. Khim. 1964, 34, 840 -
11b
Zimaity T.Afsah ES.Hammouda M. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 1979, 17: 578 -
11c
Zalukaevs LP.Vnenkovskaya DG. Zh. Org. Khim. 1966, 2: 672 -
11d
Stankevich EI.Yanags GY. J. Gen. Chem. USSR. 1962, 32: 1123 ; Zh. Obshch. Khim. 1962, 32, 1146 -
11e
Pati HN.Das U.De Clercq E.Balzarini J.Dimmock JR. J. Enzym. Inhib. Med. Chem. 2007, 22: 37 -
12a
Tu SJ.Jiang B.Zhang JY.Zhang Y.Jia RH.Li CM.Zhou DX.Cao LJ.Shao QQ. Synlett 2007, 480 -
12b
Pabolkova EA.Trukhin EV.Kasem YA.Berestovitskaya VM. Russ. J. Gen. Chem. 2006, 76: 1349 -
12c
Kozlov NG.Tarasevich VA.Vasilovskii DA.Baselaeva LI. Russ. J. Gen. Chem. 2006, 42: 107 -
12d
Pizzirani D.Roberti M.Recanatini M. Tetrahedron Lett. 2007, 48: 7120 -
12e
Chen Y.Tu SJ.Jiang B.Shi T. J. Heterocycl. Chem. 2007, 44: 1201 -
12f
Shi DQ.Ni SN.Yang F.Shi JW.Duo GL.Li XY.Wang XS.Ji SJ. J. Heterocycl. Chem. 2008, 45: 963 -
12g
Tu SJ.Jiang B.Zhang JY.Jia RH.Zhang Y.Yao CS. Org. Biomol. Chem. 2006, 4: 3980 -
12h
Li M.Yang WL.Wen LR.Li FQ. Eur. J. Org. Chem. 2008, 2751 -
13a
Song SD.Song LP.Dai BF.Yi H.Jin GF.Zhu SZ.Shao M. Tetrahedron 2008, 64: 5728 -
13b
Li XF.Song LP.Xing CH.Zhao JW.Zhu SZ. Tetrahedron 2006, 62: 2255 -
13c
Li DM.Song LP.Li XF.Xing CH.Peng WM.Zhu SZ. Eur. J. Org. Chem. 2007, 3520 -
13d
Li DM.Song LP.Song SD.Zhu SZ. J. Fluorine Chem. 2007, 128: 952 - 14
Wu DY.Ren ZJ.Cao WG.Tong WQ. Synth. Commun. 2005, 35: 3157
References and Notes
A Typical Experimental
Procedure for the Preparation of 5a
To a mixture of
ethyl 4,4,4-trifluoro-3-oxobutanoate (184.0 mg, 1.0 mmol) and 2-benzylidene-indane-1,3-dione
(468.0 mg, 2.0 mmol) in MeCN (3.0 mL) was added a catalytic amount
of pipreridine (8.5 mg, 0.1 mmol). The resulting mixture was stirred
at r.t. until the reaction was completed
(8 h, monitored
by TLC). The solvent was removed under reduced pressure. And then
the residue was purified by column chromatography on silica gel
using PE-EtOAc [6:1 (v/v)] as
eluent to afford 5a as a colorless solid
in 78% yield.
Spectroscopic
Data for Products 5
Compound 5a:
colorless solid (509.0 mg), mp 211-214 ˚C. ¹H
NMR (500 MHz, CDCl3): δ = 0.89
(t, J = 7.0
Hz, 3 H, OCH2CH
3),
3.84 (qd, J
1 = 7.0
Hz, J
2 = 3.5
Hz, 2 H, OCH
2CH3),
4.51 (d, J = 12.5
Hz, 1 H, CH), 4.56 (s, 1 H, CH), 5.19 (d, J = 12.5
Hz 1 H, CH), 5.65 (s, 1 H, OH), 6.37 (br, 1 H, ArH), 6.59-7.06
(m, 8 H, ArH), 7.32-7.42 (m, 4 H, ArH), 7.54-7.56
(m, 3 H ArH), 7.66-7.69 (m, 1 H, ArH), 7.93-7.95
(m, 1 H, ArH). ¹9F NMR (470 MHz, CDCl3): δ = -71.63
(s, 3 F, CF3). IR (KBr): 3402, 3062, 2981, 2932, 1745,
1711, 1594, 1247, 1184 cm-¹. ESI-MS: m/z = 653 [M + H]+,
670 [M + NH4]+.
Anal. Calcd for C38H27F3O7:
C, 69.94; H, 4.17. Found: C, 70.06; H, 4.06.
Compound 5b: colorless solid (510.0 mg), mp 227-229 ˚C. ¹H
NMR (500 MHz, CDCl3): δ = 0.91
(t, J = 7.0
Hz, 3 H, OCH2CH
3),
1.78 (s, 3 H, ArCH3), 2.04 (s, 3 H, ArCH3),
3.84 (qd, J
1 = 7.0
Hz, J
2 = 3.5
Hz, 2 H, OCH
2CH3),
4.47 (d, J = 12.5
Hz, 1 H, CH), 4.51 (s, 1 H, CH), 5.15 (d, J = 12.5 Hz,
1 H, CH), 5.63 (s, 1 H, OH), 6.15 (br, 1 H, ArH), 6.50-6.70
(m, 4 H, ArH), 6.82-6.86 (m, 2 H, ArH), 7.24-7.36
(m, 2 H, ArH), 7.39-7.43 (m, 2 H, ArH), 7.66-7.69
(m, 4 H, ArH), 7.92-7.93 (m, 1 H, ArH). ¹9F
NMR (470 MHz, CDCl3): δ = -71.65
(s, 3 F, CF3). IR (KBr): 3408, 3029, 2986, 1741, 1712,
1247 cm-¹. ESI-MS: m/z = 681 [M + H]+, 698 [M + NH4]+.
Anal. Calcd for C40H31F3O7:
C, 70.58; H, 4.59. Found: C, 70.33; H, 4.77.
Compound 5c: colorless solid (617.0 mg), mp 246-247 ˚C. ¹H
NMR (500 MHz, CDCl3): δ = 0.96 (t, J = 7.0 Hz,
3 H, OCH2CH
3),
3.89 (qd, J
1 = 7.0
Hz, J
2 = 3.5
Hz, 2 H, OCH
2CH3),
4.69 (d, J = 12.5
Hz, 1 H, CH), 4.71 (s, 1 H, CH), 5.20 (d, J = 12.5
Hz, 1 H, CH), 5.45 (s, 1 H, OH), 6.84-7.28 (m, 4 H, ArH),
7.43-7.53 (m, 3 H, ArH), 7.58-7.71 (m, 5 H, ArH),
7.76-7.80 (m, 2 H, ArH), 7.97-8.00 (m, 2 H, ArH). ¹9F
NMR (470 MHz, CDCl3): δ = -71.67
(s, 3 F, CF3). IR (KBr): 3420, 3058, 2979, 2934, 1746,
1710, 1595, 1248, 1188 cm-¹. ESI-MS:
743 [M + H]+, 760 [M + NH4]+.
HRMS (MALDI/DHB): m/z calcd
for [C38H25F3N2O11 + H]+: 743.1483;
found: 743.1501; m/z calcd for [C38H25F3N2O11 + Na]+:
765.1303; found:765.1309.
Compound 5d:
colorless solid (584.0 mg), mp 243-244 ˚C. ¹H
NMR (500 MHz, CDCl3): δ = 0.95
(t, J = 7.0
Hz, 3 H, OCH2CH
3),
3.87 (qd, J
1 = 7.0
Hz, J
2 = 3.5
Hz, 2 H, OCH
2CH3),
4.49 (d, J = 12.5
Hz, 1 H, CH), 4.53 (s, 1 H, CH), 5.11 (d, J = 12.5
Hz, 1 H, CH), 5.52 (s, 1 H, OH), 6.36-7.07 (m, 7 H, ArH),
7.33-7.51 (m, 4 H, ArH), 7.60-7.72 (m, 3 H, ArH),
7.72-7.75 (m, 1 H, ArH), 7.94-7.96 (m, 1 H, ArH). ¹9F
NMR (470 MHz, CDCl3): δ = -71.70
(s, 3 F, CF3). IR (KBr): 3408, 3071, 2986, 2937, 1739,
1713, 1593, 1243, 1196 cm-¹. ESI-MS: m/z = 721, 723, 725 [M + H]+,
738, 740, 742 [M + NH4]+.
Anal. Calcd for C38H25Cl2F3O7:
C, 63.26; H, 3.49. Found: C, 62.87; H, 3.58.
Compound 5e: colorless solid (551.0 mg), mp 222-223 ˚C. ¹H
NMR (500 MHz, CDCl3): δ = 0.92 (t, J = 7.0 Hz,
3 H, OCH2CH
3),
3.86 (qd, J
1 = 7.0
Hz, J
2 = 3.5
Hz, 2 H, OCH
2CH3),
4.49 (d, J = 12.5
Hz, 1 H, CH), 4.54 (s, 1 H, CH), 5.11 (d, J = 12.5
Hz, 1 H, CH ), 5.55 (s, 1 H, OH), 6.09 (br, 1 H, ArH) 6.49-6.93
(m, 6 H, ArH), 7.37-7.49 (m, 4 H, ArH), 7.56-7.60
(m, 3 H, ArH), 7.70-7.73 (m, 1 H, ArH), 7.93-7.95
(m, 1 H, ArH). ¹9F NMR (470 MHz, CDCl3): δ = -71.71
(s, 3 F, CF3), -112.61 (m, 1 F, ArF), -114.13
(m, 1 F, ArF). IR (KBr): 3397, 3087, 2983, 2938, 1743, 1711, 1511,
1247, 1190 cm-¹. ESI-MS: m/z = 689 [M + H]+.
Anal. Calcd for C38H25F5O7:
C, 66.28; H, 3.66. Found: C, 66.04; H, 3.49.
Compound 5f: colorless solid (620.0 mg), mp 241-243 ˚C. ¹H
NMR (500 MHz, CDCl3): δ = 0.94 (br,
3 H, OCH2CH
3), 3.87
(br, 2 H, OCH
2CH3),
4.51 (br, 2 H, CH), 5.13 (br, 1 H, CH), 5.58 (s, 1 H, OH), 6.34-7.01
(m, 7 H, ArH), 7.43-8.00 (m, 9 H, ArH). ¹9F
NMR (470 MHz, CDCl3): δ = -71.63
(s, 3 F, CF3). IR (KBr): 3440, 3055, 2984, 1744, 1710,
1593, 1249, 1235, 1176 cm-¹. ESI-MS: m/z = 721, 723, 725 [M + H]+,
738, 740, 742 [M + NH4]+.
Anal. Calcd for C38H25Cl2F3O7:
C, 63.26; H, 3.49. Found: C, 62.91; H, 3.37.
Compound 5g: colorless solid (743 mg), mp 265-266 ˚C. ¹H NMR
(500 MHz, CDCl3): δ = 0.95 (br, 3 H,
OCH2CH
3), 3.88 (br,
2 H, OCH
2CH3),
4.48 (br, 2 H, CH), 5.13 (br, 1 H, CH), 5.58 (s, 1 H, OH), 6.61-7.13
(m, 7 H, ArH), 7.35-7.76 (m, 8 H, ArH), 7.95-8.02
(m, 1 H, ArH). ¹9F NMR (470 MHz, CDCl3): δ = -71.61
(s, 3 F, CF3). IR (KBr): 3441, 3072, 2983, 1744, 1711,
1592, 1250, 1178 cm-¹. ESI-MS: m/z = 809, 811, 813 [M + H]+,
826, 828, 830 [M + NH4]+.
HRMS (MALDI/DHB): m/z calcd
for [C38H25Br2F3O7 + Na]+: 830.9811;
found: 830.9817.
In particular, in the cases of compounds 5f and 5g, the ¹H NMR spectrum showed broad signals due to decreased rotational flexibility of the highly puckered structures.
18CCDC 720376 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 (1223)336033.